Treatment response in multiple myeloma is measured by the detection of paraprotein in the serum and/or urine, bone marrow morphology, and immunohistochemistry. However, more effective and targeted treatments are driving a need for improved disease burden assessment at a level of sensitivity beyond what conventional methods offer. New analytical tools have emerged for the assessment of minimal residual disease (MRD), offering unparalleled sensitivity to measure trace amounts of disease.1

One such tool, clonoSEQ®, is available to ION members and is the only FDA-cleared assay for the detection and monitoring of MRD in bone marrow samples from multiple myeloma or B-cell acute lymphoblastic leukemia patients.

Powered by next-generation sequencing (NGS), clonoSEQ enables identification of residual disease down to 1 cell in a million provided sufficient sample input.2 For myeloma patients, MRD-negativity at deeper sensitivity is associated with improved overall survival and progression-free survival in both the front-line and relapsed settings.3

Explore the clinical evidence supporting
clonoSEQ MRD testing in myeloma

clonoSEQ is available to clinicians nationwide and is covered by Medicare and national private health insurers enabling access for over 165 million individuals.

Learn how to incorporate clonoSEQ into your practice by visiting

clonoSEQ is available as an FDA-cleared in vitro diagnostic (IVD) test service provided by Adaptive Biotechnologies for use in B-cell acute lymphoblastic leukemia and multiple myeloma patients to detect and monitor measurable residual disease (MRD) in bone marrow samples. clonoSEQ is also available for use in other lymphoid cancers as a CLIA-regulated laboratory developed test (LDT) service provided by Adaptive Biotechnologies. clonoSEQ is available by prescription only. For important information about the FDA-cleared uses of clonoSEQ, including test limitations, visit

1) Bal S, et al. Br J Haematol. 2019 Jul 31. [Epub ahead of print]
2) clonoSEQ®. [technical summary]. Seattle, WA: Adaptive Biotechnologies Corporation; 2018.
3) Perrot A, et al. Blood. 2018; 132(23):2456-2464

Copyright © 2019 Adaptive Biotechnologies Corp. All rights reserved.
This email was sent to because you have an account with or are a valued partner of ION Solutions. If you no longer wish to receive these types of emails, please click here to unsubscribe or update your email preferences.
AmerisourceBergen - 1300 Morris Dr Chesterbrook PA, 19087
© 2019 ION Solutions. All Rights Reserved.